Ottomin Foundation supports Breakthrough T1D with $100,000 donation. 31 August 2026 The Ottomin Foundation is proud to announce a $100,000 donation to Breakthrough T1D, presented at the Night of Champions Gala on Saturday, 29 August 2026. On the night, keynote speakers Jess and Annabelle Kovacs shared their personal experiences and the realities of living with type 1 diabetes (T1D). Held in Sydney, the Night of Champions Gala brought together NSW's T1D community, celebrities, and prominent business and philanthropic leaders for an unforgettable evening that raised $1.1 million to help advance life-changing research for type 1 diabetes. For Ottomin Foundation founders Jennie and Richard Kovacs, the commitment to T1D is driven by a personal mission to improve medical wellbeing and support meaningful progress in the fight against this lifelong autoimmune condition. The Ottomin Foundation also supports Breakthrough T1D's Type1Screen program as a multi-year donor. Type1Screen provides free screening in Australia to help identify early-stage T1D, giving individuals and families the opportunity for earlier monitoring, education, and access to research pathways. The Ottomin Foundation congratulates the Breakthrough T1D team for its leadership in research and advocacy. Through continued collaboration and community support, this work is helping move closer to a future where no one has to live with T1D.

IQVIA Clinical Decision Support Tool wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Published: 22/08/2026 | Last Updated: 23/08/2026 IQVIA Clinical Decision Support Tool has been named winner of the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year, IQVIA (NYSE:IQV) announced on August 20, 2026. The AI-enabled tool, developed by IQVIA in collaboration with Breakthrough T1D, was recognized for addressing a persistent and costly problem in diabetes care: adults with type 1 diabetes who are misclassified as having type 2 diabetes. IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. The company disclosed the award from Research Triangle Park, North Carolina, describing the recognition as validation of its expanding portfolio of artificial intelligence solutions built for clinical and commercial healthcare use cases. Misclassification between type 1 diabetes (T1D) and type 2 diabetes (T2D) is not a minor coding error. Because the two conditions require different treatment pathways, an incorrect diagnosis can delay the introduction of insulin therapy that T1D patients need, raising the risk of severe and sometimes life-threatening complications such as diabetic ketoacidosis. The IQVIA Clinical Decision Support Tool was built specifically to catch these misclassifications earlier in the care pathway, using predictive modeling to flag patient records that warrant a second look. The tool is powered by IQVIA Healthcare-grade AI(R), a proprietary framework the company says is designed to meet the accuracy, privacy and regulatory standards required for use in real clinical settings rather than experimental pilots. That distinction matters for health systems evaluating whether an AI-enabled tool is ready for production use across large patient populations. IQVIA Clinical Decision Support Tool targets type 1 diabetes misdiagnosis. The scale of the misdiagnosis problem is part of what makes the IQVIA Clinical Decision Support Tool notable. Health systems attempting to identify misclassified T1D patients manually would typically need to review tens of thousands of patient charts to find a small number of true positives, a workload that is rarely practical given constrained clinical staffing and competing priorities. By applying predictive modeling to existing patient data, the IQVIA Clinical Decision Support Tool narrows that universe dramatically before a clinician ever opens a chart. Rather than asking care teams to sift through an entire population, the tool surfaces a short, prioritized list of patients whose records show patterns consistent with a T1D profile despite a T2D diagnosis on file. JobFinder Listing That triage function is the core of why the AI Breakthrough Awards program selected the tool for its Predictive Modeling Solution of the Year category. The program recognizes innovation and performance across the global AI market, and predictive modeling applied to a well-defined clinical gap, rather than a broad or speculative use case, is precisely the kind of measurable outcome the award category is built to highlight. IQVIA Clinical Decision Support Tool delivers measurable screening gains. According to IQVIA, the results reported from deployment of the tool are substantial. The IQVIA Clinical Decision Support Tool cut the overall screening workload by 99.5%, narrowing what would have been a review of roughly 60,000 patient charts down to approximately 300, or about 200 times fewer chart reviews for care teams to complete. Diagnostic yield improved just as sharply. Among patients flagged by the tool, 28% were confirmed or suspected to have type 1 diabetes, compared with a 0.22% baseline rate of T1D confirmation in the broader unscreened population. IQVIA characterizes that shift as an approximately 127-fold increase in diagnostic yield, meaning clinical staff spend their limited chart-review time on patients who are dramatically more likely to actually have the condition the tool is designed to catch. IQVIA said the combined effect of the reduced workload and higher yield is a faster path to correct diagnosis and appropriate treatment for affected patients, which the company links to a lower risk of downstream complications and improved long-term outcomes for people living with undiagnosed or misdiagnosed T1D. Breakthrough T1D partnership shapes IQVIA Clinical Decision Support Tool rollout. The IQVIA Clinical Decision Support Tool was configured in direct partnership with Breakthrough T1D, described in the announcement as the leading global type 1 diabetes research and advocacy nonprofit organization. That collaboration shaped how the tool was built to address specific, persistent gaps in T1D care beyond diagnosis alone, including delayed identification, missed ongoing monitoring, and under-treatment once a correct diagnosis is made. Pairing a disease-specific advocacy organization with a health-data and analytics company is a deliberate design choice. Breakthrough T1D contributes clinical and patient-community context about how T1D actually presents and is missed in practice, while IQVIA contributes the data infrastructure, modeling capability and Healthcare-grade AI(R) framework needed to operationalize that knowledge at population scale across health system records. IQVIA Clinical Decision Support Tool adds to healthcare-grade AI portfolio. The 2026 AI Breakthrough Award adds to what IQVIA describes as a growing portfolio of award-winning AI solutions. IQVIA framed the recognition as reinforcement of its broader strategy of applying Healthcare-grade AI(R) to solve clinical challenges that have resisted simpler technology fixes, positioning predictive, clinically embedded tools like this one as a template for future product development. IQVIA's portfolio of solutions is powered by IQVIA Connected Intelligence(TM), which the company says combines high-quality health data, Healthcare-grade AI(R), advanced analytics and deep domain expertise into actionable insights for biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders. With approximately 94,000 employees operating in over 100 countries, IQVIA positions itself as a company built to deploy tools like the Clinical Decision Support Tool at the scale global health systems require, while maintaining what it describes as best-in-class approaches to patient privacy, regulatory compliance and patient safety throughout the AI development lifecycle. IQVIA, led by chief executive officer Ari Bousbib and headquartered in Durham, North Carolina, reported revenues of $16.3 billion for 2025. The company's decision to highlight the IQVIA Clinical Decision Support Tool win alongside its other 2026 disclosures reflects a broader pattern: IQVIA has used recent announcements, including an Everest Group ranking as the top-scored pharmaceutical technology provider for 2026 and a strategic collaboration with Medera on cardiac gene therapy research, to underscore how its data and AI capabilities extend across clinical development, commercial insight and now direct point-of-care decision support.

Greenstone bio wins $1.2M Breakthrough T1D grant for stem cell-based type 1 diabetes research. NEW YORK - Advocacy organization Breakthrough T1D said this week that it has awarded a $1.2 million grant to Greenstone Biosciences to study biologic variations in type 1 diabetes (T1D) patients. Get the full story with GenomeWeb Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month Already a GenomeWeb member? LoginLogin